SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of August 2023
Commission File Number: 001-36349
(Translation of registrant’s name into English)
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form
Form 20-F ☒
Form 40-F ☐
Appointment of New Board Member
On August 15, 2023, the Board of Directors (the "Board") of MediWound Ltd. (the "Company") appointed Mr. Shmuel (Milky) Rubinstein as a new member of the Board.
Mr. Rubinstein brings a distinguished record of pharmaceutical and biotechnology leadership to the Company. He is the Chairperson
of the Board at Trima Pharma and serves as a board member at Strata Skin Sciences (Nasdaq: SSKN), Medison Biotech, Keystone Dental and additional private companies. Additionally, Mr. Rubinstein has previously served as a director at Kamada (Nasdaq:
KMDA), Clal Biotechnology Industries (TASE: CBI), and Exalenz Bioscience, the latter of which was acquired by Meridian Bioscience. Mr. Rubinstein also held the position of CEO at Taro Pharmaceuticals (Nasdaq: TARO), which was subsequently acquired by
Mr. Rubinstein's appointment follows the tenure of Mr. Assaf Segal, who has stepped down from the Board. Mr. Segal's resignation
was not the result of any disagreement with the Company, its management, or the Board.
Incorporation by Reference
The contents of this Report of Foreign Private Issuer on Form 6-K are hereby incorporated by reference into the Company’s
Registration Statements on Form S-8, filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 and August 9, 2022 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487,
333-236635, 333-255784, and 333-266697, respectively) and on Form F-3, filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 15, 2023
By: /s/ Hani Luxenburg
Name: Hani Luxenburg
Title: Chief Financial Officer